Advances in the Research and Development of Chemotherapeutic Agents for Respiratory Tract Bacterial Infections

Cazzola, Mario; Blasi, Francesco; Centanni, Stefano; Donner, Claudio F.; Allegra, L.

doi:10.1006/pupt.2001.0302

Cited by 9 publications

(3 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are potential approaches to overcoming infections caused by multidrug-resistant strains. From genomics-based research it is possible to identify novel structural compounds that inhibit new molecular targets involved in either bacterial growth or infection [Cazzola et al 2001]. Some lines of research [Deng et al 2001;Yethon and Whitfield, 2001;Lei et al 1997] have documented that it is effective to target the infection process rather than killing bacteria.…”

Section: Novel Targetsmentioning

confidence: 99%

Review: Novel targets in the management of pneumonia

Díaz

Mortensen

Anzueto

et al. 2008

Ther Adv Respir Dis

View full text Add to dashboard Cite

Community-acquired pneumonia (CAP) is the leading cause of death from infectious diseases in the US. It accounts each year for 500,000 hospitalizations and 45,000 deaths and represents one of the most common causes of intensive care unit (ICU) admission. The mortality rate due to severe CAP has shown little improvement in the past three decades, remaining between 21% and 58% in patients admitted to the intensive care unit. Antimicrobial agents are the cornerstone of therapy against CAP, but there are some novel antibiotic and nonantibiotic therapies that have been recently tested that may potentially impact outcomes of patients with severe CAP. We will review the most recent data regarding novel therapies in patients with the highest risk of death such as those with severe CAP.

show abstract

Section: Novel Targetsmentioning

confidence: 99%

Review: Novel targets in the management of pneumonia

Díaz

Mortensen

Anzueto

et al. 2008

Ther Adv Respir Dis

View full text Add to dashboard Cite

show abstract

“…New and novel antimicrobial agents are urgently needed to meet the challenge posed by the emergence of multidrug-resistant microorganisms. Moreover, the emergence of clinical resistance to previously active antibacterial agents among many clinically significant bacterial species has had a significant impact on empiric therapy choices available to the prescribing clinician [1][2][3][4][5].…”

mentioning

confidence: 99%

Overview of tigecycline and its role in the era of antibiotic resistance

Rossi¹,

Andreazzi

2006

Braz J Infect Dis

View full text Add to dashboard Cite

The increasing antimicrobial resistance found in the many clinically important species of bacteria that commonly cause serious and life-threatening diseases presents a difficult challenge for clinicians, especially when an appropriate initial therapy must be chosen. New antibiotics are urgently needed to address the formidable issues associated with infections caused by vancomycin-resistant enterococci (VRE), methicillin-resistant Staphylococcus aureus (MRSA), penicillin-resistant Streptococcus pneumoniae and multidrug-resistant Gram-negative bacteria. The need for new antibiotics that effectively resist antimicrobial mechanisms of resistance has become paramount. Tigecycline is a new antimicrobial agent; it is the first in a new class of antibiotics, the glycylcyclines, with properties conferring the ability to overcome many common resistance mechanisms, thus allowing the use of tigecycline for many serious and life-threatening infections for which the use of other antibiotics is no longer appropriate. Tigecycline is a novel expanded spectrum antibiotic that appears poised to meet the latest bacterial challenges facing clinicians, including the serious and life-threatening infections caused by highly resistant bacteria. Tigecycline, moreover, appears to hold promise as a new, versatile antibiotic that can be chosen for empirical therapy, even as a single agent, for initial therapy of many clinically important infections.

show abstract

“…As a result of antimicrobial resistance, scientists and pharmaceutical companies must dedicate time and resources toward the active development of more potent and novel compounds to combat these pathogens [5][6][7][8][9] . A major challenge is needed to discover novel molecules that kill all microbes.…”

mentioning

confidence: 99%